CMS Withdraws Medicaid Cell, Gene Therapy Price ‘Verification’ Survey Plan

The move is positive for manufacturers and follows the agency’s decision to drop another contentious proposal that would have ‘stacked’ drug discounts when calculating Medicaid best prices.